



STATE OF WEST VIRGINIA  
DEPARTMENT OF HUMAN SERVICES  
BUREAU FOR MEDICAL SERVICES

Alex J. Mayer  
Cabinet Secretary

Cynthia Beane, MSW, LCSW  
Commissioner

**West Virginia Medicaid Drug Utilization Review Board Minutes  
05.21.2025**

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

**Members:**

Christopher Terpening, PharmD, PhD, Chair  
David Gloss, MD, Vice Chair  
Scott Brown, RPh  
Phillip Galapon, MD  
Lester Labus, MD  
Michael Lonsinger, PharmD  
Mary Nemeth-Pyles, MSN, RN, CS  
Kate Forman, PharmD  
Ernest Miller, DO

**Members Absent:**

C.K. Babcock, PharmD  
Michael Ballow, PharmD  
Chris Booth, PharmD

**Department of Human Services (DoHS)/Bureau for Medical Services (BMS) Staff:**

Vicki Cunningham, PharmD, Director of Pharmacy  
Gail Goodnight, PharmD  
Lori Moles, PharmD  
Doug Sorvig, Data Analyst  
William Hopkins, PharmD, Pharmacy Operations Manager  
Kristen Boustany, PharmD  
Kevin McCann, WV Medicaid Medical Director

**Other Contract/State Staff Present:**

Priya Shah, PharmD, Drug Utilization Review Coordinator  
Joe Bergondo, PharmD – Change Healthcare  
Roberta Capp, MD – Optum Rx  
Eric Sears, RPh -- Gainwell  
Angie Wowczuk, PharmD – Rational Drug Therapy Program (RDTP)  
Cory Chambliss – Acentra Health  
Scott Donald, PharmD – Acentra Health  
Rachele Poissant, PharmD -- Acentra Health

1. **INTRODUCTIONS**

- a. Dr. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:01 PM (EST). The DUR Board and others introduced themselves.

2. **APPROVAL OF MINUTES FROM MAY 21, 2025 DUR BOARD MEETING**

- a. Minutes for the May 21<sup>st</sup> DUR Board Meeting will be reviewed and voted on at the November 2025 DUR Board Meeting



3. **OLD BUSINESS**

- a. None

4. **NEW BUSINESS**

a. **Speakers**

- i. None

b. **Updates from August 27, 2025 Pharmaceutical & Therapeutics (P&T) Committee Meeting**

- i. Dr. Joe Bergondo presented the PDL status updates from the August 27, 2025 P&T meeting.

c. **Prior Authorization Criteria. Attachment A**

- i. **Raldesy solution** (trazodone): Approved as written, unanimously
- ii. **Symbravo** (meloxicam and rizatriptan): Approved as written, unanimously
- iii. **Tezruly solution** (terazosin): Approved as written, unanimously
- iv. **VMAT inhibitors**: Approved as written, unanimously
- v. **Multiple Sclerosis agents**: Approved as written, unanimously
- vi. **Bisphosphonates**: Approved as written, unanimously
- vii. **Calcium phosphate binders** (hyperphosphatemia agents): Approved as written, unanimously
- viii. **Nucala**: Approved as written, unanimously
- ix. **Wegovy** (addition of NASH indication): Approved with following prescriber amendment, unanimously
  - i. Must be prescribed by or in consultation with an MD/DO or a specialty trained prescriber with a clinical specialty certification/degree in gastroenterology or hepatology
- x. **Rezdiffra**: Approved with following prescriber amendment, unanimously
  - i. Must be prescribed by or in consultation with an MD/DO or a specialty trained prescriber with a clinical specialty certification/degree in gastroenterology or hepatology
- xi. **Removal of Elidel and replace with tacrolimus**: Approved as written, unanimously

5. **REPORTS—2<sup>nd</sup> QUARTER 2025**

- a. **Gainwell Technologies Quarterly Report**: Mr. Eric Sears presented an overview of the 2025 Second Quarter Report, which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program**: Dr. Angela Wowczuk presented a summary of the prior authorization program for the Second Quarter of 2025. Attachment C.
- c. **Acentra Health**: Dr. Scott Donald presented a summary of the RDUR interventions for the Second Quarter of 2025. Attachment D.

6. **OTHER BUSINESS**

- a. None

7. **NEXT MEETING AND ADJOURNMENT**

- a. The meeting concluded at 5:38 PM (EST). The next meeting will be November 19, 2025.

